Press Releases 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference 8/30/23 Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women 8/29/23 Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences 8/22/23 Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance 8/17/23 Eagle Pharmaceuticals Reports Second Quarter 2023 Results 8/8/23 Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023 8/1/23 Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance 7/31/23 Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP) 7/24/23 Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance 6/15/23 Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension 6/14/23 Pagination First page Previous page Page 1 Current page 2 Page 3 Next page Last page
